Görkem Eskiizmir

Görkem Eskiizmir

Auto-generated profile, based on publicly available information

Görkem Eskiizmir

Manisa Celal Bayar University Faculty of Medicine, Department of Otorhinolaryngology, Manisa, Türkiye

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
UUUzdan Uz
Uzdan Uz
GEGörkem Eskiizmir
Görkem Eskiizmir
Interleukin-6 (IL-6) is a proinflammatory cytokine which plays an important role in several regulatory mechanisms of cancer. Moreover, experimental and clinical studies have reported that IL-6 targeted therapies might provide significant benefits for cancer treatment. The purpose of this systematic review is to evaluate IL-6 activity in patients with head and neck squamous cell carcinoma (HNSCC). A systematic review of the association between serum, saliva and tumor IL-6 and HNSCC was developed on PubMed/Medline in the publication range from January 1995 to January 2019. Our literature analysis demonstrated that overexpression and elevated serum and/or saliva IL-6 concentrations in patients with HNSCC are related to poor survival and oncological outcomes. Although there is a correlation between IL-6 concentrations and tumorigenicity, it is noteworthy that IL-6 targeted therapies are generally performed in vitro and in experimental studies. Therefore, prospective, randomized clinical trials are required that focus on IL-6 targeted therapies for the treatment of HNSCC.

1 November 2016 in Oral Oncology
Verified
Journal Article
Closed access
GEGörkem Eskiizmir
Görkem Eskiizmir
YBYasemin Baskın
Yasemin Baskın
FYFemin Yalçın
Femin Yalçın
HEHülya Ellidokuz
Hülya Ellidokuz
RFRobert L. Ferris
Robert L. Ferris

1 November 2009 in Medical Hypotheses
Verified
Journal Article
Closed access
GEGörkem Eskiizmir
Görkem Eskiizmir
EKEric Kezirian
Eric Kezirian


11 November 2010 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
GEGörkem Eskiizmir
Görkem Eskiizmir
ZHZafer Hirçin
Zafer Hirçin
BÖBeyhan Özyurt
Beyhan Özyurt
HÜHalis Ünlü
Halis Ünlü

8 June 2018 in Brazilian Journal of Otorhinolaryngology
Verified
Journal Article
Open access
GEGorkem Eskiizmir
Gorkem Eskiizmir
UUUzdan Uz
Uzdan Uz
EOEce Onur
Ece Onur
BOBeyhan Ozyurt
Beyhan Ozyurt
GCGizem Karaca Cikrikci
Gizem Karaca Cikrikci
OCOnur Celik
Onur Celik
Systemic inflammatory biomarkers are promising predictive and prognostic factors for solid cancers. The neutrophil-lymphocyte ratio and derived neutrophil-lymphocyte ratio are used to predict inflammation and used as biomarker in several malignancies. The purpose of this study was to demonstrate the diagnostic, predictive and prognostic role of neutrophil-lymphocyte ratio and derived neutrophil-lymphocyte ratio in patients with laryngeal neoplasms. A retrospective study was conducted on medical records involving 229 patients with benign, premalignant and malignant laryngeal neoplasms between 2002 and 2015. The diagnostic, predictive and prognostic role of neutrophil-lymphocyte ratio and derived neutrophil-lymphocyte ratio were evaluated using uni- and multivariate analysis. The neutrophil-lymphocyte ratio and derived neutrophil-lymphocyte ratio were not statistically different between patients with benign, premalignant and malignant laryngeal neoplasms. Both neutrophil-lymphocyte ratio and derived neutrophil-lymphocyte ratio were predictive factors for stage, lymph node metastasis, and distant metastasis. Patients with high neutrophil-lymphocyte ratio value (≥4) had a poor prognosis when compared with patients with low neutrophil-lymphocyte ratio value (5 year, Overall Survival: 69.0% vs. 31.1%, p<0.001; 5 year, disease free survival: 70.0% vs. 32.7%, p˂0.001; 5 year, locoregional recurrence free survival: 69.7% vs. 32.0%, p<0.001). Furthermore, neutrophil-lymphocyte ratio was an independent prognostic factor for 5 year: Overall survival (HR=2.396; 95% CI 1.408-4.077; p=0.001), Disease free survival (HR=2.246; 95% CI 1.322-3.816; p=0.006) and locoregional recurrence free survival (HR=2.210; 95% CI 1.301-3.753; p=0.003). Pretreatment neutrophil-lymphocyte ratio is a useful and reliable predictive and prognostic biomarker for patients with laryngeal carcinoma.